- Intensity Therapeutics announced on **October 30, 2025**, the publication of its **Phase 1/2 IT-01 clinical study manuscript** for INT230-6 in eBioMedicine, a Lancet Discovery Science journal.  **[1567264_20251030NE10992:0]** 
- The study, involving heavily pretreated patients with advanced metastatic or refractory cancers, demonstrated a **disease control rate of 75%** (48/64 patients) and a median overall survival (mOS) of **11.9 months**.  **[1567264_20251030NE10992:0]**  For a metastatic sarcoma subset, the mOS was **21.3 months**.  **[1567264_20251030NE10992:0]** 
- In an exploratory analysis, patients receiving INT230-6 at a total dose treating greater than 40% of their total tumor burden showed a disease control rate of **83.3%** (40/48) and a median overall survival of **18.7 months**.  **[1567264_20251030NE10992:0]** 
- The safety profile indicated **no dose-limiting toxicities** among 64 monotherapy patients, with only **seven patients** (10.9%) experiencing grade 3 treatment-related adverse events and no grade 4 or 5 events.  **[1567264_20251030NE10992:0]** 
- Following these results, the company has initiated randomized controlled studies, including a **Phase 3 study in sarcoma** (NCT06263231) and a **Phase 2 study in presurgical triple-negative breast cancer** (NCT06358573).  **[1567264_20251030NE10992:1]** **[1567264_20251030NE10992:3]**

Intensity Therapeutics Announces Publication of INT230-6 Clinical Results

- Intensity Therapeutics Inc. (INTS) held a Special Meeting of Stockholders on **October 22, 2025**, with **46.13%** of outstanding voting stock present, establishing a quorum.  **[0001567264_2195806_1]** 
- Stockholders **approved** a proposal for a **reverse stock split** of common stock, with a ratio ranging from **one for five to one for 30**.  **[0001567264_2195806_1]** **[0001567264_2195806_2]**  The Board of Directors retains discretion over the exact ratio and the decision to implement the split.  **[0001567264_2195806_1]** 
- An **adjournment proposal** was also **approved**, allowing for further proxy solicitation if necessary.  **[0001567264_2195806_1]** **[0001567264_2195806_2]** 
- Final voting results will be filed in a **Form 8-K** within four business days of the meeting.  **[0001567264_2195806_2]**

Intensity Therapeutics Stockholders Approve Reverse Stock Split and Adjournment Proposals

- Intensity Therapeutics, Inc. stockholders approved a **reverse stock split proposal** at the 2025 special meeting held on **October 22, 2025**.  **[0001567264_2196805_1]** **[0001567264_2196805_2]** 
- The approved reverse stock split ratio will be **not less than one for five and not more than one for 30**, with the exact ratio and implementation timing to be determined by the Board of Directors.  **[0001567264_2196805_1]** **[0001567264_2196805_2]** 
- Stockholders also approved a proposal for the **adjournment of the special meeting** if needed to solicit further proxies.  **[0001567264_2196805_2]** 
- A quorum was established with **46.13%** of the outstanding voting stock present.  **[0001567264_2196805_1]**

Intensity Therapeutics Stockholders Approve Reverse Stock Split

- Intensity Therapeutics, Inc. stockholders **approved an amendment** to its certificate of incorporation to effect a reverse stock split of its common stock.  **[0001567264_2196799_1]** **[0001567264_2196799_2]** 
- The approved reverse stock split ratio will be **not less than one for five and not more than one for 30**, with the exact ratio to be set by the Board of Directors, who also retain the discretion to abandon the split.  **[0001567264_2196799_1]** 
- Stockholders also **approved a proposal to adjourn** the special meeting, if necessary, to permit further solicitation and vote of proxies.  **[0001567264_2196799_2]** 
- A preliminary count indicated that a **majority of votes cast** were in favor of both the reverse stock split and adjournment proposals.  **[0001567264_2196799_2]**  Final results will be disclosed in a Form 8-K within four business days of the meeting.  **[0001567264_2196799_2]**

- **Intensity Therapeutics Inc. stockholders held a special meeting on October 22, 2025**, where a quorum was established with **22,631,128 shares** present, representing **46.13% of the outstanding voting stock**.  **[0001567264_2195767_0]** **[0001567264_2195767_1]** 
- Stockholders **approved an amendment to the company's certificate of incorporation to effect a reverse stock split** of common stock.  **[0001567264_2195767_1]** **[0001567264_2195767_2]** 
- The approved reverse stock split ratio will be **not less than one for five and not more than one for 30**, with the **exact ratio and timing to be determined by the Board of Directors** in their sole discretion.  **[0001567264_2195767_1]** **[0001567264_2195767_2]** 
- Stockholders also **approved an adjournment proposal** for the special meeting, if necessary, to permit further solicitation and vote of proxies.  **[0001567264_2195767_2]**

INTENSITY THERAPEUTICS (INTS)